Ian Smith - Vertex Pharmaceuticals CFO, Executive Vice President

VRTX -- USA Stock  

USD 176.14  1.98  1.11%

  President
Mr. Ian F. Smith, CPA, is Chief Operating Officer, Executive Vice President of Vertex Pharmaceuticals Incorporated. Mr. Smith is our Executive Vice President and Chief Operating Officer, a role he assumed in September 2017. He was our Executive Vice President, Chief Operating Officer and Chief Financial Officer from January 2017 until September 2017, Executive Vice President and Chief Financial Officer from February 2006 until January 2017, our Senior Vice President and Chief Financial Officer from November 2003 to February 2006, and our Vice President and Chief Financial Officer from October 2001 to November 2003. Prior to joining us, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst Young LLP, an accounting firm, from 1999 to 2001. Mr. Smith initially joined Ernst Youngs U.K. firm in 1987, and then joined its Boston office in 1995. Mr. Smith has served as a member of the Boards of Directors of Acorda Therapeutics, Inc., a drug development company, since February 2007, and Infinity Pharmaceuticals, Inc., a drug development company, since May 2008. Mr. Smith served on the Board of Directors of Ophthotech Corporationrationration, a biopharmaceutical company, from August 2016 to May 2017
Age: 51  President Since 2017      
617-341-6100  http://www.vrtx.com
Smith holds a B.A. in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.

Ian Smith Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Christopher FenimoreRegeneron Pharmaceuticals
2017
Michael StewartPerrigo Company plc
2004
James DillardPerrigo Company plc
2019
Andrew FentonZoetis
2018
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Glenn DavidZoetis
2016
Stefan WeiskopfZoetis
2013
Samiran DasDr Reddys Laboratories Ltd
2016
Daniel PlewRegeneron Pharmaceuticals
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
John WesolowskiPerrigo Company plc
2016
James MichaudPerrigo Company plc
2016
K RaoDr Reddys Laboratories Ltd
2016
Sandra BeatyZoetis
2012
Amit BiswasDr Reddys Laboratories Ltd
2016
Peter PowchikRegeneron Pharmaceuticals
2006
Jatin ShahPerrigo Company plc
2005
Louis YuPerrigo Company plc
2013
Paul WeningerPerrigo Company plc
2015
Joyce LeeZoetis
2012
Catherine KnuppZoetis
2012

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased one share of
few hours ago
Traded for 1221.15
Purchased over 100 shares of
few hours ago
Traded for 19.55
Purchased over 40 shares of
few hours ago
Traded for 43.23
Also please take a look at World Market Map. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Search macroaxis.com